Company: HYEX
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001096906-25-001864
Chunk: 19

Company: HEALTHY EXTRACTS INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 7
Chunk 19
---
, consisted of our net loss of $727,133, plus our increase in note receivable of $391,890 and right of use asset, net-non-current of $166,086, offset in part by our decrease in inventory of $394,694, common stock issued for services of $384,150, warrants issued for services of $187,464, and lease liability-long-term of $105,219. Our net cash used in operating activities for the nine months ended September 30, 2024, consisted of our net loss of $393,742, offset in part by change in fair value on derivative liability of $273,436, warrants issued for services of $247,513, and decrease in inventory of $188,801.

Investing Activities

We had cash used in investing activities of $19,302 for the nine months ended September 30, 2025, consisting entirely of a fixed asset purchase. We had zero cash used in investing activities for the nine months ended September 30, 2024.

Financing Activities

Our net cash provided by financing activities for the nine months ended September 30, 2025 was $339,368, compared to $(159,129) for the nine months ended September 30, 2024. Our net cash provided by financing activities consisted of proceeds from issuance of notes payable-related party of $440,000 and proceeds from the issuance of notes payable of $160,000, offset by repayment of convertible debt of $146,904, repayment of notes payable-related party of $57,179, and repayment of notes payable of $56,549.

ITEM 3Quantitative and Qualitative Disclosures About Market Risk 

As a smaller reporting company, we are not required to provide the information required by this Item.

ITEM 4Controls and Procedures 

(a)Disclosure Controls and Procedures  

We conducted an evaluation, with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of September 30, 2025, to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities Exchange Commission’s rules and forms, including to ensure that information